Innovation1 Biotech

Innovation1 Biotech EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Innovation1 Biotech (IVBT) as of Oct 17, 2026 is -1,799.21 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -11.94 % — a change of 14,967.42% (lower).

EBIT/Assets

-1,799.21 %

YoY

14,967.42%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Innovation1 Biotech is 2023 -1,799.21 % . Operating Income to Assets Ratio (EBIT/Assets) of Innovation1 Biotech was 2022 -11.94 % . It decreases by 14,967.42% lower compared to the previous year.

The Innovation1 Biotech EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2016
-686.27 USD
Jan 1, 2017
-1,282.14 USD
Jan 1, 2018
-50.55 USD
Jan 1, 2019
-244.42 USD
Jan 1, 2020
-103.98 USD
Jan 1, 2022
-11.94 USD
Jan 1, 2023
-1,799.21 USD
The Innovation1 Biotech EBIT/Assets history
YEAREBIT/AssetsYoY
-1,799.21 %+14,967.42%
-11.94 %-88.52%
-103.98 %-57.46%
-244.42 %+383.52%
-50.55 %-96.06%
-1,282.14 %+86.83%
-686.27 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Innovation1 Biotech Stock analysis

What does Innovation1 Biotech do? Innovation1 Biotech Inc, based in Rockaway, New Jersey, operates in the Health Care sector, specifically within Pharmaceuticals. The company focuses on developing modified Schedule 1 molecules derived from botanical sources to create treatments for neurologic, psychiatric, dermatologic, and ophthalmologic disorders. It has a portfolio featuring five preclinical prodrugs, including a mushroom-derived psychedelic for PTSD and depression, a cannabinoid-based agent for addiction, and three additional cannabinoid prodrugs targeting pediatric epilepsy, scarring, and eye inflammation. Innovation1 Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Innovation1 Biotech stock

Operating Income to Assets Ratio (EBIT/Assets) of Innovation1 Biotech is -1,799.21 % in 2023.

Operating Income to Assets Ratio (EBIT/Assets) of Innovation1 Biotech changed from -11.94 % to -1,799.21 %, representing a 14,967.42% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Innovation1 Biotech since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Innovation1 Biotech with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Innovation1 Biotech

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Innovation1 Biotech